Advanced search

Vol 55, No 3 (2021)
Review Article
Published online: 2021-02-04

open access

View PDF Download PDF file
Supp./Additional Files
Page views 2245
Article views/downloads 1449
Get Citation

Connect on Social Media

Connect on Social Media

Genetics of Parkinson’s disease in the Polish population

Łukasz M. Milanowski123, Owen A. Ross2, Andrzej Friedman3, Dorota Hoffman-Zacharska4, Paulina Gorka-Skoczylas4, Marta Jurek4, Dariusz Koziorowski3, Zbigniew K. Wszolek1
DOI: 10.5603/PJNNS.a2021.0013
Pubmed: 33539026
Neurol Neurochir Pol 2021;55(3):241-252.

Abstract

Introduction. Genetic forms of Parkinson’s disease (PD) often cluster in different ethnic groups and may present with recognisable unique clinical manifestations. Our aim was to summarise the current state of knowledge regarding the genetic causes of PD and describe the first Polish patient with SNCA duplication.

Methodology. We searched the electronic database, PubMed, for studies between January 1995 and June 2020 that evaluated genetics in Polish patients with PD, using the search terms ‘Parkinson’s disease, ‘Polish’, ‘genetics’, ‘mutations’, and ‘variants’.

Results. In total, 73 publications were included in the review; 11 genes responsible for monogenic forms and 19 risk factor genes have been analysed in the Polish population. Pathogenic variants were reported in four monogenic genes (LRRK2, PRKN, PINK1, and SNCA). Eight genes were associated with PD risk in the Polish population (GBA, TFAM, NFE2L2, MMP12, HLA-DRA, COMT, MAOB, and DBH). Multiplex ligation-dependent probe amplification and Sanger sequencing in PRKN, PINK1, DJ1, LRRK2, and SNCA revealed SNCA duplication in a 43-year-old Polish patient with PD examined by movement disorder specialists.

Conclusion. Only a limited number of positive results have been reported in genes previously associated with PD in the Polish population. In the era of personalised medicine, it is important to report on genetic findings in specific populations.

Keywords: geneticsParkinson’s diseasePolish populationSNCA duplication

Article available in PDF format

View PDF Download PDF file

References

  1. Balestrino R, Schapira A. Parkinson disease. European Journal of Neurology. 2019; 27(1): 27–42.
    CrossRef
  2. Yoon WT. Comparison of dystonia between Parkinson's disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism. Neurol Neurochir Pol. 2018; 52(1): 48–53.
    CrossRefPubMed
  3. Siuda J, Boczarska-Jedynak M, Budrewicz S, et al. Validation of the Polish version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Neurol Neurochir Pol. 2020; 54(5): 416–425.
    CrossRefPubMed
  4. Tipton PW, Uitti RJ, Cheshire WP. 'Falling off' the dopamine wagon. Neurol Neurochir Pol. 2019; 53(5): 390–391.
    CrossRefPubMed
  5. Barc K, Kuźma-Kozakiewicz M. Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Neurol Neurochir Pol. 2019; 53(2): 99–112.
    CrossRefPubMed
  6. Gajos A, Dąbrowski J, Bieńkiewicz M, et al. Should non-movement specialists refer patients for SPECT-DaTSCAN? Neurol Neurochir Pol. 2019; 53(2): 138–143.
    CrossRefPubMed
  7. Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014; 29(13): 1583–1590.
    CrossRefPubMed
  8. Chan JCN, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009; 301(20): 2129–2140.
    CrossRefPubMed
  9. Jost WH, Altmann C, Fiesel T, et al. Influence of levodopa on orthostatic hypotension in Parkinson's Disease. Neurol Neurochir Pol. 2020; 54(2): 200–203.
    CrossRefPubMed
  10. Sauerbier A, Aris A, Lim EeW, et al. Impact of ethnicity on the natural history of Parkinson disease. Med J Aust. 2018; 208(9): 410–414.
    CrossRefPubMed
  11. Deutschländer AB. Treatment with istradefylline for postural abnormalities in Parkinson's disease. Neurol Neurochir Pol. 2019; 53(4): 239–241.
    CrossRefPubMed
  12. Szlufik S, Przybyszewski A, Dutkiewicz J, et al. Evaluating reflexive saccades and UDPRS as markers of Deep Brain Stimulation and Best Medical Treatment improvements in Parkinson's disease patients: a prospective controlled study. Neurol Neurochir Pol. 2019; 53(5): 341–347.
    CrossRefPubMed
  13. Nalls MA, Blauwendraat C, Vallerga CL, et al. 23andMe Research Team, System Genomics of Parkinson's Disease Consortium, International Parkinson's Disease Genomics Consortium. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019; 18(12): 1091–1102.
    CrossRefPubMed
  14. GBD 2016 Neurology Collaborators, GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17(11): 939–953.
    CrossRefPubMed
  15. Domingo A, Klein C. Genetics of Parkinson disease. Neurogenetics, Part I. 2018: 211–227.
    CrossRef
  16. Ambroziak W, Koziorowski D, Duszyc K, et al. Genomic instability in the PARK2 locus is associated with Parkinson's disease. J Appl Genet. 2015; 56(4): 451–461.
    CrossRefPubMed
  17. Ando M, Fiesel FC, Hudec R, et al. The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Mol Neurodegener. 2017; 12(1): 32.
    CrossRefPubMed
  18. Bialecka M, Hui S, Klodowska-Duda G, et al. Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease. Neuroscience Letters. 2005; 390(1): 1–3.
    CrossRef
  19. Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011; 89(3): 398–406.
    CrossRefPubMed
  20. Gaweda-Walerych K, Safranow K, Jasinska-Myga B, et al. PARK2 variability in Polish Parkinson's disease patients--interaction with mitochondrial haplogroups. Parkinsonism Relat Disord. 2012; 18(5): 520–524.
    CrossRefPubMed
  21. Hoffman-Zacharska D, Koziorowski D, Ross OA, et al. Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease. Parkinsonism Relat Disord. 2013; 19(11): 1057–1060.
    CrossRefPubMed
  22. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet. 2005; 76(4): 672–680.
    CrossRefPubMed
  23. Koziorowski D, Hoffman-Zacharska D, Sławek J, et al. Incidence of mutations in the PARK2, PINK1, PARK7 genes in Polish early-onset Parkinson disease patients. Neurol Neurochir Pol. 2013; 47(4): 319–324.
    CrossRefPubMed
  24. Koziorowski D, Hoffman-Zacharska D, Sławek J, et al. Low frequency of the PARK2 gene mutations in Polish patients with the early-onset form of Parkinson disease. Parkinsonism Relat Disord. 2010; 16(2): 136–138.
    CrossRefPubMed
  25. Lorenzo-Betancor O, Ogaki K, Soto-Ortolaza AI, et al. DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. Eur J Neurol. 2015; 22(9): 1323–1325.
    CrossRefPubMed
  26. Ogaki K, Koga S, Heckman MG, et al. Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology. 2015; 85(23): 2016–2025.
    CrossRefPubMed
  27. Puschmann A, Fiesel FC, Caulfield TR, et al. Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. Brain. 2017; 140(1): 98–117.
    CrossRefPubMed
  28. Ross OA, Soto AI, Vilariño-Güell C, et al. Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(7): 539–543.
    CrossRefPubMed
  29. Siuda J, Jasinska-Myga B, Boczarska-Jedynak M, et al. Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study. Parkinsonism Relat Disord. 2014; 20(11): 1274–1278.
    CrossRefPubMed
  30. Vilariño-Güell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011; 89(1): 162–167.
    CrossRefPubMed
  31. Potulska-Chromik A, Hoffman-Zacharska D, Łukawska M, et al. Dopa-responsive dystonia or early-onset Parkinson disease - Genotype-phenotype correlation. Neurol Neurochir Pol. 2017; 51(1): 1–6.
    CrossRefPubMed
  32. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006; 5(4): 355–363.
    CrossRefPubMed
  33. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998; 392(6676): 605–608.
    CrossRefPubMed
  34. Kasten M, Hartmann C, Hampf J, et al. Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Mov Disord. 2018; 33(5): 730–741.
    CrossRefPubMed
  35. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004; 304(5674): 1158–1160.
    CrossRefPubMed
  36. Watzlawik JO, Hou Xu, Fricova D, et al. Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples. Autophagy. 2020 [Epub ahead of print]: 1–16.
    CrossRefPubMed
  37. Bonifati V, Rizzu P, Squitieri F, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003; 299(5604): 256–259.
    CrossRefPubMed
  38. Moore DJ, Zhang Li, Dawson TM, et al. A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J Neurochem. 2003; 87(6): 1558–1567.
    CrossRefPubMed
  39. Funayama M, Hasegawa K, Ohta E, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol. 2005; 57(6): 918–921.
    CrossRefPubMed
  40. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004; 44(4): 601–607.
    CrossRefPubMed
  41. Lesage S, Dürr A, Tazir M, et al. French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006; 354(4): 422–423.
    CrossRefPubMed
  42. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006; 354(4): 424–425.
    CrossRefPubMed
  43. Lesage S, Leutenegger AL, Ibanez P, et al. French Parkinson's Disease Genetics Study Group. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet. 2005; 77(2): 330–332.
    CrossRefPubMed
  44. Zimprich A, Benet-Pagès A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011; 89(1): 168–175.
    CrossRefPubMed
  45. Shannon B, Soto-Ortolaza A, Rayaprolu S, et al. Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson's disease. Neurobiol Aging. 2014; 35(8): 1958.e1–1958.e2.
    CrossRefPubMed
  46. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321): 2045–2047.
    CrossRefPubMed
  47. Muenter MD, Forno LS, Hornykiewicz O, et al. Hereditary form of parkinsonism--dementia. Ann Neurol. 1998; 43(6): 768–781.
    CrossRefPubMed
  48. Book A, Guella I, Candido T, et al. SNCA Multiplication Investigators of the GEoPD Consortium. A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism. Front Neurol. 2018; 9: 1021.
    CrossRefPubMed
  49. Ibáñez P, Lesage S, Janin S, et al. French Parkinson's Disease Genetics Study Group. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol. 2009; 66(1): 102–108.
    CrossRefPubMed
  50. Fan TS, Lin HI, Lin CH, et al. Lack of CHCHD2 mutations in Parkinson's disease in a Taiwanese population. Neurobiol Aging. 2016; 38: 218.e1–218.e2.
    CrossRefPubMed
  51. Vilariño-Güell C, Rajput A, Milnerwood AJ, et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet. 2014; 23(7): 1794–1801.
    CrossRefPubMed
  52. Huttenlocher J, Krüger R, Capetian P, et al. EIF4G1is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts: Table1. Journal of Medical Genetics. 2014; 52(1): 37–41.
    CrossRef
  53. Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet. 2005; 14(15): 2099–2111.
    CrossRefPubMed
  54. Soto-Ortolaza AI, Ross OA. Genetic susceptibility variants in parkinsonism. Parkinsonism Relat Disord. 2016; 22 Suppl 1: S7–11.
    CrossRefPubMed
  55. Kim MS, Patel KP, Teng AK, et al. Genetic disease risks can be misestimated across global populations. Genome Biol. 2018; 19(1): 179.
    CrossRefPubMed
  56. Zhao F, Bi L, Wang W, et al. Mutations of glucocerebrosidase gene and susceptibility to Parkinson's disease: An updated meta-analysis in a European population. Neuroscience. 2016; 320: 239–246.
    CrossRefPubMed
  57. Jamrozik Z, Lugowska A, Kosiorowski D. Beta-Glucocerebrosidase Gene Mutations P.Asn409Ser and P.Leu483Pro in Polish Patients with Parkinson's Disease. Journal of Neurology and Neuroscience. 2015; 06(04).
    CrossRef
  58. Malec-Litwinowicz M, Plewka A, Plewka D, et al. The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease. Neurol Neurochir Pol. 2018; 52(2): 243–251.
    CrossRefPubMed
  59. Iwaki H, Blauwendraat C, Leonard HL, et al. International Parkinson's Disease Genomics Consortium. Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Mov Disord. 2019; 34(12): 1839–1850.
    CrossRefPubMed
  60. Pierzchlińska A, Białecka M, Kurzawski M, et al. The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease. Neurol Neurochir Pol. 2018; 52(4): 477–482.
    CrossRefPubMed
  61. Białecka M, Droździk M, Honczarenko K, et al. Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population. Eur Neurol. 2005; 53(2): 68–73.
    CrossRefPubMed
  62. Białecka M, Droździk M, Kłodowska-Duda G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand. 2004; 110(4): 260–266.
    CrossRefPubMed
  63. Bialecka M, Klodowska-Duda G, Kurzawski M, et al. Interleukin-10 gene polymorphism in Parkinson's disease patients. Arch Med Res. 2007; 38(8): 858–863.
    CrossRefPubMed
  64. Bialecka M, Kurzawski M, Klodowska-Duda G, et al. Polymorphism in semaphorin 5A (Sema5A) gene is not a marker of Parkinson's disease risk. Neurosci Lett. 2006; 399(1-2): 121–123.
    CrossRefPubMed
  65. Białecka M, Kurzawski M, Vlaykova T, et al. Effects of common functional MMP12 gene polymorphisms on PD in a Polish population. Neurol Neurochir Pol. 2017; 51(5): 347–353.
    CrossRefPubMed
  66. Dachsel JC, Wider C, Vilariño-Güell C, et al. Death-associated protein kinase 1 variation and Parkinson's disease. Eur J Neurol. 2011; 18(8): 1090–1093.
    CrossRefPubMed
  67. Gaweda-Walerych K, Safranow K, Maruszak A, et al. Mitochondrial transcription factor A variants and the risk of Parkinson's disease. Neurosci Lett. 2010; 469(1): 24–29.
    CrossRefPubMed
  68. Jasinska-Myga B, Wider C, Opala G, et al. GRN 3'UTR+78 C>T is not associated with risk for Parkinson's disease. Eur J Neurol. 2009; 16(8): 909–911.
    CrossRefPubMed
  69. Labbé C, Ogaki K, Lorenzo-Betancor O, et al. Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies. Neurology. 2015; 85(19): 1680–1686.
    CrossRefPubMed
  70. Müller-Nedebock AC, Brennan RR, Venter M, et al. The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects. Neurochem Int. 2019; 129: 104495.
    CrossRefPubMed
  71. Peplonska B, Safranow K, Gaweda-Walerych K, et al. TOMM40 and APOE common genetic variants are not Parkinson's disease risk factors. Neurobiol Aging. 2013; 34(8): 2078.e1–2078.e2.
    CrossRefPubMed
  72. Pepłońska B, Zekanowski C, Religa D, et al. Strong association between Saitohin gene polymorphism and tau haplotype in the Polish population. Neurosci Lett. 2003; 348(3): 163–166.
    CrossRefPubMed
  73. Puschmann A, Verbeeck C, Heckman MG, et al. Human leukocyte antigen variation and Parkinson's disease. Parkinsonism Relat Disord. 2011; 17(5): 376–378.
    CrossRefPubMed
  74. Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener. 2013; 8: 19.
    CrossRefPubMed
  75. Ross OA, Heckman MG, Soto AI, et al. Dopamine beta-hydroxylase -1021C>T association and Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(7): 544–547.
    CrossRefPubMed
  76. Soto-Ortolaza AI, Behrouz B, Wider C, et al. Calbindin-1 association and Parkinson's disease. Eur J Neurol. 2010; 17(2): 208–211.
    CrossRefPubMed
  77. Tan EK, Drozdzik M, Bialecka M, et al. Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci Lett. 2004; 372(3): 240–244.
    CrossRefPubMed
  78. von Otter M, Landgren S, Nilsson S, et al. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med Genet. 2010; 11: 36.
    CrossRefPubMed
  79. Truban D, Hou Xu, Caulfield TR, et al. PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology? J Parkinsons Dis. 2017; 7(1): 13–29.
    CrossRefPubMed
  80. Noack H, Bednarek T, Heidler J, et al. TFAM-dependent and independent dynamics of mtDNA levels in C2C12 myoblasts caused by redox stress. Biochim Biophys Acta. 2006; 1760(2): 141–150.
    CrossRefPubMed
  81. Gaweda-Walerych K, Maruszak A, Safranow K, et al. Mitochondrial DNA haplogroups and subhaplogroups are associated with Parkinson's disease risk in a Polish PD cohort. J Neural Transm (Vienna). 2008; 115(11): 1521–1526.
    CrossRefPubMed
  82. Liu Y, Zhang M, Hao W, et al. Matrix metalloproteinase-12 contributes to neuroinflammation in the aged brain. Neurobiol Aging. 2013; 34(4): 1231–1239.
    CrossRefPubMed
  83. Michałowska M, Chalimoniuk M, Jówko E, et al. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease. Brain Behav. 2020; 10(3): e01537.
    CrossRefPubMed
  84. Labbé C, Ogaki K, Lorenzo-Betancor O, et al. Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinson's Disease Locus. PLoS One. 2015; 10(6): e0128586.
    CrossRefPubMed
  85. Mizuta I, Tsunoda T, Satake W, et al. Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. Hum Genet. 2008; 124(1): 89–94.
    CrossRefPubMed
  86. Krygowska-Wajs A, Kachergus JM, Hulihan MM, et al. Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism. J Neural Transm (Vienna). 2005; 112(11): 1487–1502.
    CrossRefPubMed
  87. Krygowska-Wajs A, Hussey JM, Hulihan M, et al. Two large Polish kindreds with levodopa-responsive Parkinsonism not linked to known Parkinsonian genes and loci. Parkinsonism Relat Disord. 2003; 9(4): 193–200.
    CrossRefPubMed
  88. Figura M, Friedman A. In search of Parkinson's disease biomarkers - is the answer in our mouths? A systematic review of the literature on salivary biomarkers of Parkinson's disease. Neurol Neurochir Pol. 2020; 54(1): 14–20.
    CrossRefPubMed
  89. Schneider SA, Alcalay RN. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. J Neurol. 2020; 267(3): 860–869.
    CrossRefPubMed
  90. Fiandaca MS, Lonser RR, Elder JB, et al. Advancing gene therapies, methods, and technologies for Parkinson's Disease and other neurological disorders. Neurol Neurochir Pol. 2020; 54(3): 220–231.
    CrossRefPubMed
  91. Padmanabhan S, Polinski NK, Menalled LB, et al. The Michael J. Fox Foundation for Parkinson's Research Strategy to Advance Therapeutic Development of PINK1 and Parkin. Biomolecules. 2019; 9(8).
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note